Dilemmas in new Tibetan medicine R&D, critical appraisal of strategies, and phased implementation pathways
Objective To review the current status and challenges of new Tibetan medicine research and development (R&D) and to construct a phased implementation pathway, with critical appraisal of the strategies for each dilemma. Methods A narrative review using literature analysis and inductive synthesis was conducted. CNKI, Wanfang Data, VIP, PubMed, and Web of Science were searched, and policies and standards were collected from regulatory websites. Current status and challenges were analyzed across five dimensions (resource security, standardization and quality control, research and talent, clinical evaluation and translation, and collaborative regulation), and an implementation pathway was constructed on this basis. Dilemmas were defined by explicit criteria, and strategies were graded by evidence strength. Results The main problems are as follows. Wild Tibetan medicinal material resources have declined severely, and domestication, equivalence evaluation, and resource baseline surveys lag behind. Quality standard coverage is low, and safety evaluation that distinguishes the chemical forms of mineral medicines is lacking. Interdisciplinary talent is scarce, and the modern elucidation of theory, the application of intelligent technologies, and evidence-based capacity are weak. Few medical institutions have completed drug clinical trial institution filing, human-use experience is rarely converted into registration evidence, and current review requirements fit the Tibetan “three-cause” theory poorly. Collaboration among R&D actors is weak, and regulation lacks dedicated review standards that reflect the characteristics of Tibetan medicines. The proposed pathway starts from resource security and advances in near-term (2026–2030), mid-term (2031–2035), and long-term (from 2036) phases, with completion markers, linkage conditions, responsible parties, and funding sources specified for each phase. Resource surveys and standard setting can start now; the three-combination evidence system needs data infrastructure; theory translation and artificial intelligence remain exploratory. Conclusion New Tibetan medicine R&D should rest on the textual verification of medicinal material resources and their ecologically sustainable supply. A “Tibetan medicine theory-human-use experience-clinical trial” three-combination system for review should be established, the quality standard system improved, and the scientific elucidation of Tibetan medicine theory deepened. Innovation platforms should strengthen talent cultivation and basic research, clinical evaluation specifications consistent with Tibetan medicine should be formulated, and a differentiated regulatory model should be adopted.
Authors
- Haoling Zhang (ORCID: https://orcid.org/0009-0004-3413-5277)
- Feiyan Zhao (ORCID: https://orcid.org/0000-0002-7360-5436)
- Zhenzhen Qian
- Zhuoga Danzeng (ORCID: https://orcid.org/0000-0003-1837-8709)
- Rui Gao (ORCID: https://orcid.org/0000-0003-2455-7615)
- Yiming Ren (ORCID: https://orcid.org/0000-0003-0188-0583)
- Xinyue Dai
- Guoyuan Zhang
- Qin Xu
- Quzhu RenQing
Institutions
- Nanjing University of Chinese Medicine (CN)
- Tibet University (CN)
- Beijing University of Chinese Medicine (CN)
- China Resources (China) (CN)
- Xiyuan Hospital (CN)
- Suzhou Traditional Chinese Medicine Hospital (CN)
- China Academy of Chinese Medical Sciences (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.3389/fphar.2026.1962794
- Primary Topic
- Traditional Chinese Medicine Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- China Academy of Chinese Medical Sciences